Home > Publications Database > Exploring blood-based biomarkers in late-life depression: Correlates of psychotherapeutic treatment outcomes. > print

001     285023
005     20260226110040.0
024 7 _ |a 10.1192/j.eurpsy.2026.10153
|2 doi
024 7 _ |a pmid:41572662
|2 pmid
024 7 _ |a 0924-9338
|2 ISSN
024 7 _ |a 1778-3585
|2 ISSN
037 _ _ |a DZNE-2026-00148
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Martino-Adami, Pamela V
|0 0000-0002-1067-1495
|b 0
245 _ _ |a Exploring blood-based biomarkers in late-life depression: Correlates of psychotherapeutic treatment outcomes.
260 _ _ |a Cambridge
|c 2026
|b Cambridge University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772097726_7491
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Major depressive disorder is a prevalent and debilitating mental health condition contributing to a growing global burden. Late-life depression (LLD), affecting individuals over 60 years of age, is further associated with elevated risks for cardiovascular diseases, cognitive decline, and dementia. Treatment responses vary widely, potentially due to underlying neurodegeneration and cellular senescence. We aimed to explore blood-based biomarkers related to Alzheimer's disease and senescence-associated secretory phenotype (SASP) proteins, seeking to identify biological underpinnings of LLD and their association with response to psychotherapy.We performed a secondary analysis of the Cognitive Behavioral Therapy for Late-Life Depression (CBTlate) trial in 228 participants aged 60 years and older with a diagnosis of LLD. Depression trajectories were compared using clustering. In participants with available plasma samples, biomarker data were generated post hoc. We assessed associations between biomarkers and depression trajectories, biomarker dynamics, and their ability to predict treatment response.Two depression trajectories were identified: persistently high stable Geriatric Depression Scale (GDS) scores (hsGDS) and decreasing scores over time (dGDS). The hsGDS group had more severe baseline depression (p = 2.88 × 10-6), anxiety (p = 4.39 × 10-4), and sleep disorders (p = 1.09 × 10-3), and was more likely to have a history of major depression (p = 0.01) and mild cognitive impairment (p = 0.01). Biomarker analysis revealed elevated baseline plasma neurofilament light chain (NfL, p = 2.51 × 10-2) and reduced C-X-C Motif Chemokine Ligand 5 (CXCL5, p = 2.83 × 10-2) in the hsGDS group. Including CXCL5 in predictive models improved trajectory differentiation (p = 3.94 × 10-3).Cellular aging biomarkers like CXCL5 may improve understanding of LLD and guide personalized therapeutic interventions.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a blood-based biomarkers
|2 Other
650 _ 7 |a cellular senescence
|2 Other
650 _ 7 |a late-life depression
|2 Other
650 _ 7 |a neurodegeneration
|2 Other
650 _ 7 |a psychotherapeutic treatment outcome
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Major Depressive Disorder: therapy
|2 MeSH
650 _ 2 |a Major Depressive Disorder: blood
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cognitive Behavioral Therapy
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 1
|u dzne
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 2
700 1 _ |a Bewernick, Bettina
|b 3
700 1 _ |a Domschke, Katharina
|b 4
700 1 _ |a Luppa, Melanie
|0 0000-0003-3927-6728
|b 5
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 6
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 7
|u dzne
700 1 _ |a Frölich, Lutz
|0 P:(DE-2719)9001189
|b 8
700 1 _ |a Riedel-Heller, Steffi
|0 0000-0003-4321-6090
|b 9
700 1 _ |a Schramm, Elisabeth
|b 10
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 11
700 1 _ |a Dafsari, Forugh S
|0 0000-0002-9549-9208
|b 12
773 _ _ |a 10.1192/j.eurpsy.2026.10153
|g Vol. 69, no. 1, p. e18
|0 PERI:(DE-600)2005377-0
|n 1
|p e18
|t European psychiatry
|v 69
|y 2026
|x 0924-9338
856 4 _ |u https://pub.dzne.de/record/285023/files/DZNE-2026-00148%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/285023/files/DZNE-2026-00148.pdf
856 4 _ |u https://pub.dzne.de/record/285023/files/DZNE-2026-00148%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/285023/files/DZNE-2026-00148%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/285023/files/DZNE-2026-00148%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/285023/files/DZNE-2026-00148.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:285023
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2000057
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)2811024
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2812825
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-04T14:28:44Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-04T14:28:44Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR PSYCHIAT : 2022
|d 2024-12-16
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR PSYCHIAT : 2022
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 0
920 1 _ |0 I:(DE-2719)1011303
|k AG Heneka
|l Neuroinflammation, Biomarker
|x 1
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 2
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1011303
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1011201
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21